Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.

Immunotherapy - 1 Jun 2017

Araújo Manuel, Ligeiro Dário, Costa Luís, Marques Filipa, Trindade Helder, Correia José Manuel, Fonseca Candida

Abstract excerpt

Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fulminant Type 1 diabetes induced by treatment with anti-programmed cell death-1 monoclonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Diabetes Mellitus, Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ Antigens

Share to HLA-DR3 Antigen

Share to HLA-DR4 Antigen

Share to Immunotherapy

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Source

Identifiers

PMID: 28595520
DOI: 10.2217/imt-2017-0020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.PMID 28595520Read ↗

Fulminant Type 1 Diabetes Induced by Immune Checkpoint Inhibitors in a Patient with Autoimmune Predisposition.Semantic proximity Read ↗

Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.Semantic proximity Read ↗

HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.Semantic proximity Read ↗

Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung CancerSemantic proximity Read ↗

Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient‐derived induced pluripotent stem cells for future researchSemantic proximity Read ↗

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Nivolumab-associated DRESS in a genetic susceptible individual.Semantic proximity Read ↗

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.Semantic proximity Read ↗

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer.Semantic proximity Read ↗

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in JapanSemantic proximity Read ↗

Molecular scanning of the gene for programmed cell death-1 (PDCD-1) as a candidate for type 1 diabetes susceptibility.Semantic proximity Read ↗

Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.